Recent advances in drug treatment for choroidal neovascularization in patho-logical myopia
10.13389/j.cnki.rao.2025.0013
- VernacularTitle:病理性近视脉络膜新生血管的药物治疗新进展
- Author:
Ninghui ZHANG
1
;
Xiaofeng XIE
;
Qingmei TIAN
;
Hongsheng BI
Author Information
1. 250014 山东省济南市,山东中医药大学
- Publication Type:Journal Article
- Keywords:
choroidal neovascularisation;
anti-vascular endothelial growth factor;
efficacy comparison;
optical co-herence tomography
- From:
Recent Advances in Ophthalmology
2025;45(1):66-70
- CountryChina
- Language:Chinese
-
Abstract:
Pathological myopic choroidal neovascularization(PM-CNV)is a common complication leading to vision loss in patients with pathological myopia.Its pathogenesis involves various factors,including mechanical traction,hypoxia,and inflammation.Anti-vascular endothelial growth factor therapy has been proven to be effective in the treatment of PM-CNV.Clinical trials have demonstrated that anti-vascular endothelial growth factor drugs,such as ranibizumab,aflibercept,and conbercept,can improve the vision of patients with PM-CNV,each with its characteristics and applicable scope.This article reviews the latest advancements in drug treatment for PM-CNV,aiming to provide valuable reference for the clinical management of this disease.
